Long-term salivary function after conditioning with busulfan, fractionated or single-dose TBI

Oral Diseases

Volumn 17, Issue 7, 2011, Pages 670-676

  Garming Legert, Karin ^a   Remberger, M ^b   Ringden O ^b   Hassan, M ^b   Dahllof G ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Busulfan; Cancer; Children; Oral; Pharmacokinetics; Saliva

Indexed keywords

ACICLOVIR; BUSULFAN; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; CYTARABINE; FLUDARABINE; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; RAPAMYCIN; TACROLIMUS;

ADOLESCENT; AREA UNDER THE CURVE; ARTICLE; CORRELATION ANALYSIS; DRUG BLOOD LEVEL; DRUG EXPOSURE; FEMALE; GRAFT VERSUS HOST REACTION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HERPES VIRUS INFECTION; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RADIATION DOSE FRACTIONATION; SALIVA ANALYSIS; SALIVATION; SEX DIFFERENCE; WHOLE BODY RADIATION;

ADOLESCENT; AGE FACTORS; ANEMIA, APLASTIC; AREA UNDER CURVE; BUSULFAN; CYCLOPHOSPHAMIDE; DOSE FRACTIONATION; FEMALE; GRAFT VS HOST DISEASE; GRANULOMATOUS DISEASE, CHRONIC; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; LEUKEMIA, MYELOID, ACUTE; LONGITUDINAL STUDIES; LYMPHOHISTIOCYTOSIS, HEMOPHAGOCYTIC; LYMPHOMA, T-CELL; MALE; MYELODYSPLASTIC SYNDROMES; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; SALIVARY GLANDS; SECRETORY RATE; SEX FACTORS; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, HOMOLOGOUS; WHOLE-BODY IRRADIATION;

EID: 80052568379     PISSN: 1354523X     EISSN: 16010825     Source Type: Journal    
DOI: 10.1111/j.1601-0825.2011.01821.x     Document Type: Article

References (35)

1. Adkins DR, Dipersion JF (2008). Total body irradiation before an allogeneic stem cell transplantation: is there a magic dose? Curr Opin Hematol 15: 555-560.
2. Aschan J (2007). Risk assessment in haematopoietic stem cell transplantation: conditioning. Best Pract Res Clin Haematol 20: 295-310.
3. Bågesund M, Winiarski J, Dahllöf G (2000). Subjective xerostomia in long-term surviving children and adolescents following pediatric bone marrow transplantation. Transplantation 69: 822-826.
4. Cosset JM, Girinsky T, Malaise E et al (1990). Clinical basis for TBI fractionation. Radiother Oncol 18(Suppl. 1): 60-67.
5. Crossner CG (1984). Salivary flow rate in children and adolescents. Swed Dent J 8: 271-275.
6. Dahllöf G, Heimdahl A, Bolme P (1988). Oral condition in children treated with bone marrow transplantation. Bone Marrow Transplant 3: 43-51.
7. Dahllöf G, Krekmanova L, Kopp S et al (1994). Craniomandibular dysfunction in children treated with total-body irradiation and bone marrow transplantation. Acta Odontol Scand 52: 99-105.
8. Dahllöf G, Bågesund M, Remberger M et al (1997). Risk factors for salivary dysfunction in children 1year after bone marrow transplantation. Oral Oncol 33: 327-331.
9. Dawes C (2004). How much saliva is enough for avoidance of xerostomia. Caries Res 38: 236-240.
10. Garming Legert K, Remberger M, Ringdén O et al (2011). Salivary secretion in children after fractionated or single-dose total body irradiation. Bone Marrow Transpl. In press.
11. Garthon G, Ringdén O (1997). Benmärgs och stamcellstransplantation. Garthon G, Lundh B, eds. Blodsjukdomar - Lärobok i Hematolog. Third edn. Natur och kultur, Inc: Stockholm, Sweden, pp. 440-448.
12. Hassan M, Oberg G, Bekassy AN et al (1991). Pharmacokinetics of high-dose busulphan in relation to age and chronopharmacology. Cancer Chemother Pharmacol 28: 130-134.
13. Hassan M, Fasth A, Gerritsen B et al (1996). Busulphan kinetics and limited sampling model in children with leukemia and inherited disorders. Bone Marrow Transplant 18: 843-850.
14. Hassan M, Ljungman P, Ringdén O et al (2000). The effect of busulphan on the pharmacokinetics of cyclophosphamide and its 4-hydroxy metabolite: time interval influence on therapeutic efficacy and therapy-related toxicity. Bone Marrow Transplant 25: 915-924.
15. Jensen SB, Pedersen A, Vissink A et al (2010). A systematic review of salivary gland hypofunction and xerostomia induced by cancer therapies: prevalence, severity and impact on quality of life. Supp Care Cancer 18: 1061-1079.
16. Kosuda S, Satoh M, Yamamoto F et al (1999). Assessment of salivary gland dysfunction following chemoradiotherapy using quantitative salivary gland scintigraphy. Int J Radiat Oncol Biol Phys 45: 379-384.
17. Krause DS (2005). Engraftment of bone marrow-derived epithelial cells. Ann N Y Acad Sci 1044: 117-124.
18. Lagasse E, Connors H, Al Dhalimy M et al (2000). Purified hematopoietic stem cells can differentiate into hepatocytes in vivo. Nat Med 6: 1229.
19. Ljungman P, Hassan M, Békássy AN et al (1997). High busulfan concentrations are associated with increased transplant-related mortality in allogeneic bone marrow transplant patients. Bone Marrow Transplant 20: 909-913.
20. Lundgren G, Wilczek H, Lönnqvist B et al (1985). Acyclovir prophylaxis in bone marrow transplant recipients. Scand J Infect Dis Suppl 47: 137-144.
21. Mattsson J, Jansson M, Wernerson A et al (2004). Lung epithelial cells and type II pneumocytes of donor origin after allogeneic hematopoietic stem cell transplantation. Transplantation 78: 154-157.
22. Ness KK, Carter A, Rosenthal J (2005). Performance limitations and participation restrictions among childhood cancer survivors treated with hematopoietic stem cell transplantation: the bone marrow transplant survivor study. Arch Pediatr Adolesc Med 159: 706-713.
23. Oeffinger KC, Mertens AC, Sklar CA et al (2006). Chronic health conditions in adult survivors of childhood cancer. N Engl J Med 355: 1572-1582.
24. Remberger M, Svahn B-M, Hentschke P et al (1999). Effect on cytokine release and graft-versus-host disease of different anti-T-cell antibodies during conditioning for unrelated haematopoietic stem cell transplantation. Bone Marrow Transplant 24: 823-830.
25. Ringdén O, Deeg HJ (1996). Clinical spectrum of graft-versus-host disease. Ferrara JLM, Deeg HJ, Burakoff S, eds. Graft vs Host Disease, 2nd edn. Marcel Dekker, Inc: New York, USA, pp. 525-559.
26. Ringdén O, Le Blanc K (2005). Allogeneic hematopoietic stem cell transplantation: state of the art and new perspectives. APMIS 113: 813-830.
27. Ringdén O, Remberger M, Persson U et al (1995). Similar incidence of graft-versus-host disease using HLA-A, -B and -DR identical unrelated bone marrow donors as with HLA-identical siblings. Bone Marrow Transplant 15: 619-625.
28. Ringdén O, Hermans J, Labopin M et al (1996). The highest leukaemia-free survival after allogeneic bone marrow transplantation is seen in patients with grade I acute graft-versus-host disease. Acute and chronic leukaemia working parties of the European group for blood and marrow transplantation (EBMT). Leuk Lymphoma 24: 71-79.
29. Ringdén O, Remberger M, Ruutu T et al (1999). For the Nordic Bone Marrow Transplantation Group. Increased risk of chronic graft-versus-host disease, obstructive bronchiolitis and alopecia using busulfan compared to total body irradiation: long-term results of a randomized trial in allogeneic marrow recipients with leukemia. Blood 93: 2196-2201.
30. Ringdén O, Remberger M, Svanberg P et al (2007). Fludarabine-based disease-specific conditioning or conventional myeloablative conditioning in hematopoietic stem-cell transplantation for treatment of non-malignant diseases. Bone Marrow Transplant 39: 383-388.
31. Schaffer M, Aldener-Cannavá A, Remberger M et al (2003). Roles of HLA-B, HLA-C and HLA-DPA1 incompatibilities in the outcome of unrelated stem-cell transplantation. Tissue Antigens 62: 243-250.
32. Schuler U, Schroer S, Kühnle A et al (1994). Busulfan pharmacokinetics in bone marrow transplant patients: is drug monitoring warranted? Bone Marrow Transplant 14: 759-765.
33. Storb R, Deeg HJ, Fisher L et al (1988). Cyclosporine vs methotrexate for graft-v-host disease prevention in patients given marrow grafts for leukemia: long-term follow-up of three controlled trials. Blood 71: 293-298.
34. Thomson WM (2005). Issues in the epidemiological investigation of dry mouth. Gerodontology 22: 65-76.
35. Zander D, Cogle C, Theise N et al (2006). Donor-derived type II pneumocytes are rare in the lungs of allogeneic hematopoietic cell transplant recipients. Ann Clin Lab Sci 36: 47-52.